Search

Arthur E Warrington

from Rochester, MN
Age ~64
Get Report
Also known as:
Arthur Edward Warrington, Arthur R Warrington, Author E Warrington, Arthur E Kennedy, Arth Warrington, Warrington Arth
Phone and address:
2004 15Th St, Rochester, MN 55906
Related to:
Nick J Draine, 45
Connected to:
Aaron D Warrington, 40Alex S Warrington, 29Amanda R Warriner, 34Anastasia N Warriner, 40Anna W Warriner, 102Annie E Warrington, 33Beth M Warriner, 61Bill D Warrington, 92Brandon Warrington, 42Brenda Warriner, 76

Arthur Warrington Phones & Addresses

  • 2004 15Th St, Rochester, MN 55906
  • 2704 5Th St, Rochester, MN 55901
  • 2794 5Th St, Rochester, MN 55901
  • Manchester, CT
  • Gaithersburg, MD
  • Rockville, MD
  • Washington, DC
  • 29 Hudson St, Manchester, CT 06042

Work

Company: National institutes of health Sep 1993 to Sep 1997 Position: Postdoctoral fellow

Education

School / High School: East Catholic High School

Industries

Hospital & Health Care

Resumes

Resumes

Arthur Warrington Photo 1

Research Scientist

View page
Location:
29 Hudson St, Manchester, CT 06042
Industry:
Hospital & Health Care
Work:
National Institutes of Health Sep 1993 - Sep 1997
Postdoctoral Fellow
Mayo Clinic Sep 1993 - Sep 1997
Research Scientist
Education:
East Catholic High School
Trinity College

Publications

Us Patents

Compositions And Methods Including A Recombinant Human Mab That Promotes Cns Remyelination

View page
US Patent:
20070086999, Apr 19, 2007
Filed:
May 17, 2004
Appl. No.:
10/557115
Inventors:
Elliot Gruskin - Malvern PA, US
Eric Chojnicki - Houston TX, US
Arthur Warrington - Rochester MN, US
Allan Bieber - Rochester MN, US
Moses Rodriguez - Rochester MN, US
International Classification:
A61K 39/395
A61K 31/573
US Classification:
424145100, 514171000
Abstract:
Antibodies, and particularly human antibodies, are disclosed that demonstrate activity in the treatment of demyelinating diseases as well as other diseases of the central nervous system that are of viral, bacterial or idiopathic origin, including dysfunction caused by spinal cord injury. Neuromodulatory agents are set forth that include and comprise a material selected from the group consisting of an antibody capable of binding structures or cells in the central nervous system, a peptide analog, a hapten, active fragments thereof, agonists thereof, mimics thereof, monomers thereof and combinations thereof. Methods are described for treating demyelinating diseases, and diseases of the central nervous system of humans and domestic animals, using polyclonal IgM antibodies and human monoclonal antibodies sHIgm22(LYM 22), sHIgm46(LYM46) ebvHIgM MSI19D10, CB2bG8, AKJR4, CB2iE12, CB2iE7, MSI19E5 and MSI10E10, active fragments thereof and the like. The invention also extends to the use of human antibodies, fragments, peptide derivatives and like materials, and their use in above referenced therapeutic applications, and to pharmaceutical compositions containing them, that may be administered in desirably low doses to treat conditions involving demyelination and to promote remyelination.

Human Monoclonal Antibodies Against Amyloid Beta Protein, And Their Use As Therapeutic Agents

View page
US Patent:
20110027288, Feb 3, 2011
Filed:
Mar 24, 2009
Appl. No.:
12/934773
Inventors:
Moses Rodriguez - Rochester MN, US
Larry R. Pease - Rochester MN, US
Arthur E. Warrington - Rochester MN, US
Nilufer Taner - Jacksonville FL, US
International Classification:
A61K 39/395
A61P 25/28
US Classification:
4241421
Abstract:
Materials and methods for identifying human natural anti-Aβ autoantibodies, as well as materials and methods for using such antibodies to treat Alzheimer's disease.

Human Antibodies And Diagnostic And Therapeutic Uses Thereof For The Treatment Of Neurological Disease

View page
US Patent:
20130280167, Oct 24, 2013
Filed:
Oct 19, 2011
Appl. No.:
13/880415
Inventors:
Moses Rodriguez - Rochester MN, US
Arthur E. Warrington - Rochester MN, US
Larry R. Pease - Rochester MN, US
International Classification:
A61K 39/395
US Classification:
424 91, 5303891, 4241721, 5303913, 536 2353, 435 696, 435 721
Abstract:
Specific binding members, particularly human antibodies, particularly recombinant antibodies, and fragments thereof, which are capable of binding to and recognizing neurons in the CNS and eliciting responses in CNS neurons are provided. The antibodies are useful for neuroprotection and in the diagnosis and treatment of conditions associated with nerve damage, injury or degeneration and neurodegenerative disease. The antibodies, variable regions or CDR domain sequences thereof, and fragments thereof of the invention may also be used in therapy in combination with chemotherapeutics, immune modulators, or neuroactive agents and/or with other antibodies or fragments thereof. Antibodies are exemplified by the antibodies IgM12 and IgM42 whose sequences are provided herein.

Compositions And Methods Including A Recombinant Human Mab That Promotes Cns Remyelination

View page
US Patent:
20130309240, Nov 21, 2013
Filed:
Mar 7, 2013
Appl. No.:
13/788529
Inventors:
Elliot A. Gruskin - Malvern PA, US
Eric Chojnicki - Houston TX, US
Arthur E. Warrington - Rochester MN, US
Allan J. Bieber - Rochester MN, US
Moses Rodriguez - Rochester MN, US
International Classification:
A61K 39/395
US Classification:
4241421
Abstract:
Antibodies, and particularly human antibodies, are disclosed that demonstrate activity in the treatment of demyelinating diseases as well as other diseases of the central nervous system that are of viral, bacterial or idiopathic origin, including neural dysfunction caused by spinal cord injury. Neuromodulatory agents are set forth that include and comprise a material selected from the group consisting of an antibody capable of binding structures or cells in the central nervous system, a peptide analog, a hapten, active fragments thereof, agonists thereof, mimics thereof, monomers thereof and combinations thereof. Methods are described for treating demyelinating diseases, and diseases of the central nervous system of humans and domestic animals, using polyclonal IgM antibodies and human monoclonal antibodies sHIgm22(LYM 22), sHIgm46(LYM46) ebvHIgM MSI19D10, CB2bG8, AKJR4, CB2iE12, CB2iE7, MSI19E5 and MSI10E10, active fragments thereof and the like. The invention also extends to the use of human antibodies, fragments, peptide derivatives and like materials, and their use in above referenced therapeutic applications, and to pharmaceutical compositions containing them, that may be administered in desirably low doses to treat conditions involving demyelination and to promote remyelination.

Human Antibodies And Diagnostic And Therapeutic Uses Thereof For The Treatment Of Neurological Disease

View page
US Patent:
20200397898, Dec 24, 2020
Filed:
May 7, 2020
Appl. No.:
16/869344
Inventors:
- Rochester MN, US
Arthur E. Warrington - Rochester MN, US
Larry R. Pease - Rochester MN, US
International Classification:
A61K 39/395
C07K 16/18
Abstract:
Specific binding members, particularly human antibodies, particularly recombinant antibodies, and fragments thereof, which are capable of binding to and recognizing neurons in the CNS and eliciting responses in CNS neurons are provided. The antibodies are useful for neuroprotection and in the diagnosis and treatment of conditions associated with nerve damage, injury or degeneration and neurodegenerative disease. The antibodies, variable regions or CDR domain sequences thereof, and fragments thereof of the invention may also be used in therapy in combination with chemotherapeutics, immune modulators, or neuroactive agents and/or with other antibodies or fragments thereof. Antibodies are exemplified by the antibodies IgM12 and IgM42 whose sequences are provided herein.

Treatment Of Neonatal Hypoxia Including Impairments Or Effects Thereof

View page
US Patent:
20170355754, Dec 14, 2017
Filed:
Nov 6, 2015
Appl. No.:
15/524058
Inventors:
- Rochester MN, US
Arthur E. Warrington - Rochester MN, US
Moses Rodriguez - Rochester MN, US
William A. Carey - Rochester MN, US
International Classification:
C07K 16/18
A61K 39/395
A61K 45/06
A61K 39/00
Abstract:
The invention provides methods for the treatment of neonatal hypoxia and associated white matter disease or injury, particularly in infant, including neonatal, animals, particularly Periventricular Leukomalacia (PVL) comprising administering one or more CNS reactive antibody, particularly selected from IgM12, IgM22, IgM42 and IgM46. Compositions for use in treatment of white matter disease or injury in infants, particularly PVL are provided. The invention provides methods for alleviation of neuromotor or neurodevelopmental deficits associated with neonatal hypoxia and associated with white matter injury, including PVL, in an infant.

Compositions And Methods Including A Recombinant Human Mab That Promotes Cns Remyelination

View page
US Patent:
20150299316, Oct 22, 2015
Filed:
Jan 23, 2015
Appl. No.:
14/603553
Inventors:
Elliott A. Gruskin - Malvern PA, US
Arthur E. Warrington - Rochester MN, US
Allan J. Bieber - Rochester MN, US
Moses Rodriguez - Rochester MN, US
Eric Walter Theodore Chojnicki - Ladera Ranch CA, US
International Classification:
C07K 16/28
A61K 39/395
A61K 31/573
Abstract:
Antibodies, and particularly human antibodies, are disclosed that demonstrate activity in the treatment of demyelinating diseases as well as other diseases of the central nervous system that are of viral, bacterial or idiopathic origin, including neural dysfunction caused by spinal cord injury. Neuromodulatory agents are set forth that include and comprise a material selected from the group consisting of an antibody capable of binding structures or cells in the central nervous system, a peptide analog, a hapten, active fragments thereof, agonists thereof, mimics thereof, monomers thereof and combinations thereof. Methods are described for treating demyelinating diseases, and diseases of the central nervous system of humans and domestic animals, using polyclonal IgM antibodies and human monoclonal antibodies sHIgm22(LYM 22), sHIgm46(LYM46) ebvHIgM MSI19D10, CB2bG8, AKJR4, CB2iE12, CB2iE7, MSI19E5 and MSI10E10, active fragments thereof and the like. The invention also extends to the use of human antibodies, fragments, peptide derivatives and like materials, and their use in above referenced therapeutic applications, and to pharmaceutical compositions containing them, that may be administered in desirably low doses to treat conditions involving demyelination and to promote remyelination.

Human Antibodies And Specific Binding Sequences Thereof For Use In Stroke And Ischemia Or Ischemic Conditions

View page
US Patent:
20150104460, Apr 16, 2015
Filed:
Apr 17, 2013
Appl. No.:
14/395141
Inventors:
- Rochester MN, US
Arthur E. Warrington - Rochester MN, US
Larry R. Pease - Rochester MN, US
International Classification:
C07K 16/18
A61K 39/395
A61K 45/06
A61K 51/10
US Classification:
4241421, 53038815, 5303873, 5303913, 5303917, 536 2353, 435 696, 435 721
Abstract:
Specific binding members, particularly human antibodies, particularly recombinant antibodies, and fragments thereof, which are capable of binding to and recognizing neurons in the CNS and eliciting responses in CNS neurons are provided. The antibodies are useful in the diagnosis and treatment of conditions associated with nerve damage, injury or degeneration and neurodegenerative disease, and in particular in the treatment or alleviation of stroke or cerebral ischemia. The antibodies, variable regions or CDR domain sequences thereof, and fragments thereof of the invention may also be used in therapy in combination with chemotherapeutics, immune modulators, or neuroactive agents and/or with other antibodies or fragments thereof. The antibodies or active fragments thereof may be used in therapy for stroke or cerebral ischemia alone or in combination with thrombolytics such as TPA. Antibodies are exemplified by the antibodies IgM12 and IgM42 whose sequences are provided herein.
Control profile
Arthur E Warrington from Rochester, MN, age ~64 Get Report